NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
2.33 ^USD	+4.48%		+8.37%	-67.37%

Jul. 11	Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	CI
Jul. 11	Novabay Pharmaceuticals Reports Preliminary Revenue Results for the Second Quarter and First Half of 2024	CI

PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market

January 17, 2023 at 06:50 am EST

PhaseOne Health announced the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals' patented, stable hypochlorous acid.

Latest news about NovaBay Pharmaceuticals, Inc.

Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	Jul. 11	CI
Novabay Pharmaceuticals Reports Preliminary Revenue Results for the Second Quarter and First Half of 2024	Jul. 11	CI
NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities	Jul. 01	MT
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. Commence Co-Promotion Activities	Jul. 01	CI
NovaBay Files Registration Statement on Behalf of Selling Shareholders	Jun. 21	MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M	May. 09	MT
Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M	Mar. 26	MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc..	Mar. 24	CI
NovaBay Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2023	Mar. 14	CI
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. for $1.07 million.	Mar. 13	CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	Mar. 13	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	Jan. 09	CI
Transcript : NovaBay Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $3.3M, vs. Street Est of $3.55M	Nov. 09	MT
Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft	23-09-14	CI
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft	23-09-11	MT
NovaBay Pharmaceuticals, Inc. Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova®? Allograft	23-09-11	CI
Ladenburg Thalmann Cuts Price Target on NovaBay Pharmaceuticals to $3.80 From $6, Maintains Buy Rating	23-08-11	MT
Transcript : NovaBay Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10

Chart NovaBay Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for NovaBay Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.33 USD

Average target price

58.62 USD

Spread / Average Target

+2,416.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVABAY PHARMACEUTICALS, INC.	-67.37%	2.68M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research